FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 ...

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

The German biotech firm reaffirmed its full-year guidance and reported lower operating expenses alongside a solid cash ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.